Alaunos Therapeutics, Inc.

Q4 2022 Earnings Conference Call


spk_0: thank you for standing by welcome to the a lot of therapeutic fourth quarter two thousand and twenty two financial results conference call at this time all participants learn a lesson only mode after the speakers presentation there will be a question and answer session to ask a question during the session your or press star one one on your telephone you will then here and ah automated message advised the new your hand as raised to withdraw your question please post star one one again please be advised that the day conference or being recorded i would now like the i'm a conference over the your speaker today danielle dungeon with stern i are please go ahead
spk_1: good morning welcome to the a loner therapeutics fourth quarter and full year twenty twenty to finance a result conference call and audio webcast earlier this morning alone of issued a press release announcing financial results for the three month and full year and a december thirty first twenty twenty two the encourage everyone to read today's press release as well as the alone and annual report on form pancake for the year ended december thirty first twenty twenty two which was filed with the with the see this morning the company's press release and anywhere for it will also be available on the a lot of let's say a lot of dot com in addition the conference call with being webcast through the investor relations section of the company's website it will be archived there for future reference please note that very information disgust on to they call it covered under the safe harbor provisions of the private securities litigation reform act of nike ninety five participants are caution that the conference thousand in time sensitive information that it's accurate only other the day of this live broadcast march seven twenty twenty three actual results could differ materially from those seated or implied by forward looking statements made today due to rest and answer it is associated with the company's business information on potential risks and uncertainties are set forth and our most recent public finally with the se si se si dot gov the company under six no obligation to revise or up the any forward looking statements to reflect events or circumstances after the day of the forecast accepted may be required by a portable security flaw with me today or kevin boiled finger chief executive officer through gallagher vice president of research and development rb srivastava vice president affected cooperation in my long vice president of finance with that said i would like to turn the call over the cabin
spk_2: a good annual good morning and thank you for joining us today for an update on the exciting progress we're making here in along us
spk_3: twenty twenty two was a transformational year for a long as therapeutics as we achieved several meaningful corporate milestones including advancing our library pc or to sell programmed into the clinic and subsequently achieving our first objective clinical response we're a highly focused company committed to leading the scientific development of tea cell receptor therapies to revolutionize solid cancer treatment and improve patient outcomes i'm extremely proud of our teams work and realizing the promise of our novel technologies and already efforts with clinical execution we believe tc or t targeting high frequency driver mutations is potentially the most promising advanced immunotherapy to kill solid tumors we are proud to be on the leading edge of cell therapy we're the first company to demonstrate an objective clinical response in a patient with a solid tumor using a non viral pcr t cell therapy we are encouraged and motivated by the significant interest these results that since generated among physicians patients investors potential partners and other key stakeholders every day multiple patients are reaching out to inquire into our clinical study from across the country this growing momentum provides a tremendous foundation for the year ahead we have been hard at work to ensure that we can meet our t c or t library phase one to program milestones in twenty twenty three in the fourth quarter we filed an iron the amendment for the trial as part of this amendment we made several critical enhancements to our enrollment and manufacturing processes first we combined are treatment and screen protocols streamlining a moment making it easier for both patients and physicians second we are no longer required to recast the patience tumor mutation if more than six months has passed between screening and treatment which will allow for faster a cool we are confident that these driver mutations will be retained as they are at the core of the cares lastly we added cryopreservation to our manufacturing process while reduces the manufacturing process time from thirty days to twenty six days while simultaneously increasing flexibility for patients scheduling and treatment as we look ahead cryopreservation also allows us to open additional trial sites outside of texas and yes contrary to the common belief of many taxes there is a big world outside of this great state in this expansive i am the amendment we again added to our industry leading see our library for use against solid cancers with to new tc ours targeting frequent mutations and a chalets this edition effectively doubles our eligible patient pool for the study with now more than ten percent of all patient screen for our trial and md anderson matching a library tc on taken together we are confident that these changes will enable us to increase the piece of enrollment in or trial allowing us to become face to ready by the end of the year i'd like to talk about our to crt library phase one to trial and what does your will look like as we move towards phase two readiness as you recall this is a basket trial targeting driver mutations across sick solid tumor indications non small cell lung colon and i'm a tramp pancreas ovary and bile duct cancers we are actively rolling patients it md anderson with any one of these six cancers based on matching both a specific mutation and h l a combination to a tc are that is available in our library
spk_2: as a result of the most recent i the amendment our gcr library now consists of twelve she's yours five k ras six tp fifty three and one good year for
spk_3: in december we successfully dose the third patient in the trial this patient was diagnosed with pancreatic cancer with a tumor expressing h a a eleven and key west you twelve v mutation matching one of the to see ours within our see our library
spk_2: the patient was treated at the second dose level with fifty eight billion tc or t cells
spk_3: as with the first two patients patient three had a manageable safety profile with no deal keys or i cans observed the flexibility of our platform is astonishing when the first three patients on the study representing three distinct indications being treated with three different she's yours as we treat additional patients we believe that presenting safety and efficacy data on multiple patients at the same time is the most credible clinically meaningful and industry standard practice and we look forward to sharing additional patient three data with other patient results later this year we will remain flexible on what venues we used to provide patient updates when we provide updates and how many patients will be included in each update based on what is in the best interest of the company in total we anticipate trading between twelve and fifteen patients in the phase one portion of the trial with three patients having been dose than twenty twenty two we are confident that are growing patient pipeline and manufacturing capacity will support treating the remaining balance of patients this year our resolve and commitment to developing the best in class tc or t cell therapies has been strengthened by the growing momentum we're seeing in the patients and physicians interest in our trial oh beforehand the call over to drew i'll briefly speak to our financial position in december we completed a follow on offering where we raised approximately fifteen million dollars and gross proceeds despite the most challenging market conditions facing the biotech industry over the past five years as responsible stewards of the company the board carefully evaluated all available financing options and firmly believe that this was a right decision to allow the company to continue to advance our pioneering science for perspective and twenty twenty two only fifty eight follow on financings were completed compared over two hundred and the years prior as one of the few companies to close a financing at market terms with out issuing warrants the promise of our science and technology was recognized by investors the additional cash is allowed us to extend our runway into the fourth quarter and should enable us to accelerate the enrollment of patience and the manufacturing of clinical products to generate additional meaningful clinical data this year well let me and the call over to drew to highlight our ongoing the efforts and discuss where we see opportunities to explore next generation c r t cell therapies to further deep and clinical responses
spk_4: through
spk_3: thank you kevin i'm excited to share today that we were pushing full speed ahead and are and the efforts we continue to ramp up our hundred teach your discovery platform to increase the number of patients who can benefit from the pcr he felt there
spk_5: we are generating foundational data from the translational assessments and are treated patients and we are using the translational data a guy in our next generation peace yards he still endeavors that will fuel our pipeline for the long term
spk_3: let me start with hunter we continue to strongly believe that hunter is that the cutting edge of innovation and have significant advantages over traditional pcr discovery methods we've been very successful in identifying novel exclusively owned mutate and react to pc ours and are emboldened to increase throughput and focus on high value targets
spk_5: our teeth yards or source from t cells infiltrating a tumor expressing the driver mutation in the natural context of a chalet
spk_3: we can then use that he's yard to add to the library for the benefit of another patient who have the same target at the twenty twenty two fifty conference we presented proof of concept data supporting hunters ability to evaluate hundreds of thousands of h allays mutations and pcr combinations and a high throughput standing with our proprietary technology as kevin reference and the fourth quarter we added two new t or so our library targeting frequent driver mutations and a lives
spk_5: the addition of these two tc ours has had a major impact on the potential address will market for our t crt program effectively doubling
spk_3: we are pleased to show now a greater than a ten percent match rate and the patient pre screening process the addition of these new to see ours is a prime example of are two pronged library expansion strategy on one hand we are working to add more a chili's to the existing k ras pp thirty three and eg of our mutations in the library which we did by adding v r o seven decay rashid twelve v
spk_5: on the other hand we're adding new mutations within our targeted gene families which we did with tp fifty three or two seventy three see this year we expect to grow the library to fifteen tc tcs
spk_3: and over time we imagined that the library could be above forty two years to expand the number of patients that could potentially benefit from our to crt for there
spk_5: we believe i'm a of is uniquely situated to effectively deliver more than one pcr to a patient on a commercial scale which we call multiplexing from a therapeutic perspective multiplex thing is advantageous because the more targets we attacked the better chances we have of achieving long term durable rick missions of cancer we are highly encourage them roughly one in five of our pain patients match to more than one t c r in our library right now
spk_3: multiplexing to therapy is therefore a unique opportunity for us in the near term we expect the number of patients was single and multiple matches to continue to grow as we expand the library
spk_5: and given the pace of our hunter successes we believe we can further weaponized t c r t cells to benefit patients with driver mutations
spk_3: our non viral sleeping beauty system enables us to build the library of t v r's quickly and cost effectively in a way that we believe no other company can
spk_5: in addition to expanding the address will mark in and reach of our t v rt self therapy through the t share a library we are also using our translational data from the clinical trial to help guide our next generation pcr t efforts we'll make data driven decisions to address factors relevant for limiting exhaustion and maximizing the therapeutic potential of rtc r t cells
spk_3: we're delighted to say that we have detective persistence of our to therapy cells in the peripheral blood without exhaustion marker such as pt one
spk_6: further we have observed factor cells and a diverse group of tea some memory subsets including team them race
spk_3: themselves
spk_5: posts freedom biopsies of retained the targeted h l a mutation
spk_3: he sells grown from post treatment biopsies contain c r t cells capable of responding to the appropriate driver mutation and therefore our cells are making it to the tumor microenvironment and are functional
spk_5: this is what we were hoping to see and are thrilled to have these translational data with the sleeping beauty t crt it's very
spk_3: we continue to develop novel strategies that generate ip for the company and build upon our early successes while being supported by the translational assessments we routinely engage with our scientific advisory board chaired by doctor paul june leading experts at md anderson and a host of other advisors consultant think he opinion leaders on these topics who believe in the promise of our platform and support our trailblazing path given our demonstration of proof of concept we are marching towards commercialization of the first ever driver mutation r t self therapy
spk_7: now let me turn the called over to rb to highlight the tremendous progress his team has been making in our manufacturing process hobby
spk_8: thank you do has given and do have discussed it continue to be very excited about the progress we're making in our t v rt library time last year while the critical earphones as he initiated family efforts to advance and accelerate our clinical problem i'd like to highlight the mid efforts first we have successfully manufactured at milan as gmp seed see patients product you wouldn't see different t v ours in see defend tumor indication all three manufactured products had fantastic characteristics the leading to liability purity and ppr positivity our manufacturing process was consistently for the pcr in our library it effective off mutations are a challenge second we have doubled our manufacturing capacity by implementing new apple beef that allow for simultaneous production up multiple products in our dmp seat on time we continue to invest dual boot process development what are you finding our manufacturing back from in the fourth quarter of twenty twenty to be worth to for that optimize our manufacturing process who am i envy the amendment your move from press to cryopreserved health products kyle enabled us to reduce the manufacturing process time from thirty two twenty six days representing a thirteen percent decrease i'm happy to report that the have already implemented the prior manufacturing process this year if new profit now provides us with greater flexibility for patients scheduling and treatment with the possibility to collect the basement a fleece is early on in their treatment government we can been manufactured the dot product and cardio preserve it until the patient is ready for been fusion this is a good start an hour long term goal is to further reduce the manufacturing time to fifteen days i'm so proud of our fully committed technical operations team and hour universal peace yard manufacturing back from
spk_9: and i mean excited about the investment we are making in process development that will close the person automate the process and decrees the cost was preparing us for phase two i would now like the tone the call or what the might want to the view the financial results for the fourth quarter and folio my thank you rb allow me to review our finances are the three months ended december thirty first country country to for the fourth quarter of twenty twenty two the are reported of net loss of approximately nine point two million dollars or a for sense that last pressure compared to a net loss of approximately eleven point eight million dollars or a five cent that boss per share but the same period and twenty twenty one research and development expenses were approximately five point six million dollars for the fourth quarter of twenty twenty two compared to approximately eight point two million dollars by the fourth quarter of twenty twenty one a decrease of thirty two percent a decrease as primarily due to reduce program related costs and lower on fire related and consulting expenses general and administrative expenses were approximately two point nine million dollars for the fourth quarter of twenty twenty two compared to approximately two point one million dollars by the fourth quarter of twenty twenty one an increase of approximately eight hundred thousand dollars which has primarily due to hire legal and accounting expenses our operating cash ban by the fourth quarter of twenty twenty two as approximately seven point one million dollars compared to approximately fifteen point five million dollars and the fourth quarter of twenty twenty one a decrease of approximately eight million dollars or fifty three percent and now our review the results for the full year ended december thirty first twenty twenty two for the year ended december thirty first twenty twenty two we're apart and that loss of approximately thirty seven point seven million dollars or seventeenth and net loss per share compared to a net loss of approximately seventy eight point eight million dollars or thirty seven sent net loss per share of the year ended december thirty first twenty twenty one and impressive year over year action a fifty two percent collaboration revenue as approximately two point nine million dollars a year ended december thirty first twenty twenty two compared to approximately four hundred thousand dollars for the year ended december thirty first twenty twenty one the increase in collaboration revenue was primarily did the achievement that filthy mouth and of down a person in japan which has largely off that i a one time research and development expense that are touch on shortly research and development expensive were approximately twenty five million dollars for the year ended december thirty first plenty twenty two compared to approximately forty nine point six million dollars a year ended december thirty first twenty twenty one a decrease a fifty percent a decrease in research and development expenses as primarily due to read this program related costs and lower empire related and consulting expensive these decreases were partially offset by a one time two point five million dollar milestone payment md anderson for down a person had a year twenty twenty two general and administrative expenses were approximately thirteen point one million dollars compared to approximately twenty seven point six million dollars but the year ended december thirty first twenty twenty one a decrease fifty two priests said the decrease in general and administrative expenses as primarily due to lower higher related and professional therapist expenses as of december thirty first tiny tiny to elena had approximately fifty three million dollars in cash balances which includes restricted cache of approximately thirteen point nine million dollars serving as collateral for outstanding debt our operating cash ban for the year ended december thirty first twenty twenty two with approximately twenty nine point two million dollars compared to approximately sixty one point five million dollars for the year ended december thirty first twenty twenty like a decrease of approximate lee thirty two point two million dollars or fifty two percent reflecting the follow your impact of our cost reduction efforts and are focused on the and good stewards of capital based on our current operating plans we expect our operating cash flows excluding that service costs for twenty twenty three to be between approximately thirty five to forty million dollars we expect to have sufficient cash resources to fund research and development programs and operations and a queue for of twenty twenty three i want to highlight some other work we are doing on the corporate side to further build upon our growing momentum a line of as the leader and t crt targeting driver mutations and as a lot to further solidify the peasants and ray that profile among the industry and media the recently engaged six degrees and established public relations firm specializing in and serving the biotech industry
spk_10: are innovative technology and exciting clinical programmer remain on the cutting edge of research lucky cr and solid camera space and we look forward to engaging with and building relationships with media audiences
spk_3: in addition to six degrees the recently engaged additional investorrelations resources to cultivate existing and develop new and better relationships i would now like to turn the car kevin for closing remarks thank you mike as we look to the year ahead we're dedicated to revolutionizing how solid tumors are being treated using our disruptive technology and the clinical manufacturing and research teams are committed to the subjective
spk_2: through the groundwork we have laid in our recent i'm the i'm and where we added additional tc ours and transition the crowd preservation we will greatly enhance patient throughput and treatments what's ability for a cheesy or t library phase one to trial
spk_3: we remain confident a positive momentum we have built among patients and physicians will lead to even greater accomplishments as we expect to treat the remaining balance of patience in the phase one portion of our c or t library trial share additional patient data and become phase two ready by the end of the year looking beyond twenty twenty three we envision being in the face to stage of our existing i andy our idea enables us to conduct in multiple independent indication specific phase two trials simultaneously often times certain she's yours may be associated with specific cancer types for instance now small cell lung cancer commonly has eg fr and key rest mutations so we may expect to enroll lung cancer patients with predominantly these tc ours colon cancer on the other hand is associated with rest ntp thirty three mutations which could be a second phase two trial over time we expect to initiate multiple phase two trials across several solid schumer indications as we believe our cheesy archie cell therapy as of portability across a broad range of solid schumer types to our knowledge we are the only company taking this type of unique approach utilizing the t c our library targeting driver mutations against solid tumors as we continue to build a long term potential or tc or t cell therapies from milan us we are actively developing next generation treatments which hold the potential to deepen clinical responses from combination approaches and multi pledged gcr t cell therapies we are working to conduct translational assessments of treated patients to guide these next gen produce in the near term our membrane bound i'll fifteen pc or t cell therapy program is advancing towards and i md which we anticipate submitting later this year we remain very optimistic about our hunter to see our discovery platform which is firing on all cylinders by expanding the library with proprietary tc ours we increase the addressable market and the number of patients that might benefit from are single or multiplex gcr t cell therapies
spk_0: it is truly astonishing what this platform is capable of and i look forward to what the future holds for hunter in some bolstered by the early and encouraging clinical results we believe twenty twenty three will prove to be an exciting year filled with promise in progress on us as we advance our pipeline of innovative tc arthur service
spk_11: i want to express my deepest gratitude to our patience shareholders and employs for their support as we continue our mission to improve the lives of patients with solid tumors we will now open the called a questions michelle thank you as a reminder please press star one one on your telephone and wait for your name to the announced can withdraw your question please press dar one one again one moment while we compile the queue in a roster
spk_3: i first question on the line of cracker as a while with cancer your line of often please go ahead i are by flooding my questions and on that on for you for a community my my first question have there been any some serve those since patient and mcqueen few forgiven enormous progress of the key focus for the company will appreciate any color here i'm just to confirm that he had a green light from the of be others but the can add cements to the i'd be and there are no the regulatory approvals required and article a couple of on of the car good morning good hear from you with regards to patient in rome and as we said we're very excited about the progress that is being made in the interest in this trial stemming from our first objective clinical response we are in not going to report on a patient by patient basis but we're going to look for the right venue to provide further updates on number of patients treated and the data associated with that but we're feeling quite confident based on the interests that his grown and the excitement around the response
spk_11: once in the data that we've seen thus far out of the first three patients and with regards to the i and the mm in in the fourth quarter where we added to additional tc ours and made certain enhancements and the clinical trial designed to further facility and accelerate the enrollment there are no outstanding questions from the i the which is really shown are unique trial design in the relationship with
spk_3: with the agency the fact that we have had multiple i in the amendments with very minimal comment so this is a a a unique trial design for sure one that we believe as a differentiator for this company in a in quite a positive way and very excited about these driver mutations are benefiting cancer patients gotta thank you i know second question the opportunity for multiplex pcr was loaded in the personally leave the comments or patients who are matching far more than one piece years maybe for can expand on how this will be this could be implemented in the trial will it be a separate id and a from the beginning van on the find a pick rational form of ecstasy or and you
spk_5: absolutely our drew comment on that
spk_3: the gaga morning think for the question we're very excited about the potential for multiplexing odd of it's a tv for now though we're excited to see that roughly one in five of our patients a mess one of the tc hours on their pre screening process of more than one match to do think that this is something that's feasible or as we think that for a sleeping beauty non biosystem we have a unique position to deliver more than one pcr that the your point about the rationale is going back to him more than one target at a given time as more than one chance to affect the cancer
spk_12: so we're excited about that
spk_0: and we're looking forward to bringing in i'll fifteen as ira and the second half of this year for a nine the amendment maybe even potentially adding that multiplexing an altar i thank you
spk_13: thank you and one moment fine next question an expression cause a line of yell can with
spk_3: laidlaw lie your line of up and please go ahead a blood money and think i think into question the ah my first question is that the in terms of the you characterize the the i felt that there had a certain characteristics ah could you elaborate more in terms of whether those as that are functional or and and have a follow up as well morning he'll yes a great question they for the question was very excited below were saying of the translational assessments and all and then specifically in regards to the cells that are persisting in the blood of our patients that have been treated are showing limited access
spk_13: bush and were saying the memory stem cells and then within the gym the biopsies that have happened post treatment we've seen retention of the actually and the mutation by the tumor and he fell to be grown from those to immersive pills have had to are thousand those are in thief functional against the driver mutation so really encourage that ourselves are getting their they look to be functional on a book to have limited exhaustion okay great at very helpful media follow up here with kids that are giving you guys thought to progress will a bit more
spk_3: in two more paper that and cutler and goes ah are you by thinking about any potential be a business development opportunities and ah if so how would build things could be you know a final characterized the that the you leave it only retain retainer a good portion of the the at that and how sure yeah like like all biotechs were always an active discussion with potential partners and business development opportunities are very excited about the interest that are t crt platform or eating driver mutation has generated within a discussions with other folks and were also very motivated by the potential of our hunter platform we really believe that is quite interesting and novel because we can develop
spk_13: true this very high put throughput of single celled sequencing that drew as mentioned identify novel targets with proprietary
spk_9: i p so a very strong patent position both to bolster our own tc our library of k ras tp fifty three and eg fr mutations but at the same time hunter identifies and has the capability of identifying other novel targets that would be of interest to potential partner so we really have something special here and i believe strongly that others see that very opportunity and potential as well
spk_13: okay great that they're very helpful baby a weekend lot more are you currently i'd film you have a certain level of debt ah who hall which what the i thought in managing that and the thing
spk_0: thanks thanks to the question as a here and are outstanding that balance was approximately sixteen point seven million dollars police started principal repayments and september of twenty twenty two and we expect to have that fully repaid by august of this year
spk_5: okay great than i appreciate
spk_3: thank you and my moment fine next question i liked question comes on the line of commerce flatten with lake street your line up and please go ahead a good morning thanks for taking the questions at kevin i was on if you could expand a little bit more on a what qualifies us phase two ready i'd from the patient number any of the things we should be looking for their was good morning when we looked towards what we want to accomplish in the phase one first and foremost it's about safety it's identifying a maximum tolerated dose and then it's also identifying the recommended face kudos so those are going to be the three items that we look for safety maximum tolerated those recommended face to dose and what's really nice is this beijing design allows us to accelerate achieving this objective and that is why a relatively low patient number and phase one is all that's required to achieve these objects so as you may recall thomas we only had a ddos one patient at the first those level
spk_14: and because of the favorable safety profile that we've seen were able to accelerate that to the second dose level so we're we're very excited we also have a higher dose level you may recall because of the safety profile should be rather favorable the targets were going after these driver mutations by definition brenda the core of the heart of the
spk_15: cancer and do not appear on healthy tissue cells like some of our other tc our competitors that are targeting different targets so we believe we have a superior target in our driver mutation with our gcr is going after these targets that are only in the cells of the cancer and therefore we can use hi
spk_3: higher doses and we believe that a lead to greater efficacy that's great a appreciate the color and the in enrollment target the you have a of twelve to fifteen i can we assume that that would be achievable with the current ah stable of teach yourself so the twelve or does that imply that you're going to have of at a few more during the year in order the hit that hit animal model oh i i tell you we feel very confident with the number of patients that we're seeing and are pipeline any additional tc ours are just building towards the future building towards our goal of multiplexing so you know you it as a reminder any time we added ccr we can absolutely use it to start treating patients right away but so we're very confident with what we see right now with the engagement of r p eyes and md anderson that with our phase one we will be successful in treating their work required number of patients and will do so in a very expeditious manner and we have our own manufacturing capacity with our own employees being able to the execute on that being able to manufacture multiple products at the same time and what's nice with this as well with the cryopreservation thomas' were able to see
spk_5: our manufacturing now earlier in the patients journey so we can manufacture products it can be waiting in the freezer for when unfortunately at the treatment fails a patient we can then take their product that we made early and twenty twenty three and and fuse that patient when they're ready so it's it's really a very important enhancement that we made we believe we're going to end up with more fit cells by taking the a for he says earlier in the patients journey we can manufacture that product cryopreserved the cells and then be ready for that patient when unfortunately if their failure
spk_3: their current therapy fails them excellent and then swan final one to just the think we have a manufacturing i believe the of he said during the call that the goal was to reduce the manufacturing a timeline from twenty six the fifteen days i'll just wondering if you to comment on
spk_8: what's required to hit that goal and over what time frame we might expect to see you guys kind of little that timing down store and and i do think our be hit some of the aspects the kind of three aspects within
spk_16: that that we're working on addition reducing costs but are the ones you go ahead and talk after tunguska yeah tom so
spk_8: we're we're investing multi prong manufacturing strategy to really cut down our manufacturing time we are constantly investing in process development ah loading loading the piston providing the automation in our manufacturing bad farm and by doing so we're very confident that will be able to reduce the my
spk_3: in fact and time ah to the fifteen days as reach to the commercial i this mistake a complex thing the question oh sorry sorry sorry go ahead and just wanted to highlight the the how much cryopreservation has provided us the power of flexibility baby's lagging that guy preservation will be able to manufacture the better product and and overhaul i forget the out the upper call but when i called the at the bucket
spk_16: yeah thomas just important i think to highlight here is one of the things that crop reservation does when fresh tells you had a patient that was ready to be infused immediately so timing really mattered right now the fact that we're able to manufacture the cells ahead of time in this phase one portion of the trial with the crowd preservation
spk_17: whether it's twenty six days or fifteen days it's still earlier in the patients journey where they're not quite ready to be infused yet so the time is less relevant at this stage so we have the time to be able by the time as rb be said when we hit commercial it'll be reduced that will be very important but as of right now the
spk_0: time frame taking a manufacturing the cells is less relevant because the cells will be frozen down and be available immediately when the patient is ready
spk_18: excellent appreciated think i guess

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.